DelNova to be featured in the upcoming list of Top 10 Biotech Startups 2022 as Editor’s Choice, on Life Sciences Review Magazine...
Watch the video presentation....
Presentation to highlight ReViVox™, DelNova's lead product candidate designed for treating complications resulting from undesirable muscle paralysis following botulinum neurotoxin (e.g. Botox®) procedures SAN DIEGO and CHICAGO, May 29, 2019 /PRNewswire/ -- DelNova, a biopharmaceutical company developing clinically validated molecules linked to advances in drug delivery, announced today that its...
